02-Nov-2026 08:07:21
SUNPHARMAAcquisition and merger
CITI ON SUN PHARMA ; BUY | TP ₹2,280
• US Ilumya execution challenges may take a few quarters to resolve; psoriatic arthritis launch planned in November. • Organon acquisition expected to close in Q4 FY27. • R&D spending likely to increase in H2 FY27. • Cuts FY27–29 EBITDA estimates by 8–12%. • Leqselvi and Unloxcyt remain key growth opportunities.
SUN PHARMACEUTICAL IND L